background: radiation absorbed dose to the red bone marrow, a critical organ in the therapy of thyroid carcinoma, is generally kept below 2 gy for non-myeloablative therapies. the aim of this study was to calculate bone marrow radiation dose by using mirdose3 package program and to optimize the safe limit of activity to be administered to the thyroid cancer patients. materials and methods: in t...

Introduction: Hyperthyroidism is a relatively common disorder caused by different etiologies. Graves’ disease, and toxic-nodular goiter (Plummer’s disease) are among the most common causes. Treatment with radioiodine is considered to be the treatment of choice in many of the patients. Higher biological half-life of ¹³¹I in hyperthyroid patients as compared with patients with differentiate...

Hyperthyroidism is a common disease and one of the best methods for its treatment is radioiodine therapy. Treatment with antithyroid drugs brings patients to euthyroidism before radioiodine therapy. Antithyroid drugs should be discontinued before radioiodine therapy to increase thyroid uptake. The purpose of this study was to determine the optimal time of methimazole (MTZ) discontinuation...

Introduction Radioiodine is a safe and effective treatment for Graves’ disease. Iatrogenic hypothyroidism is very common after treatment, but its onset is unpredictable. Even a short episode of hypothyroidism can result in significant morbidity and ideally should be avoided. In Newcastle a standard dose of radioiodine (400MBq) is used, but for historical reasons two different protocols are used...

Radioiodine is regularly used in the treatment of thyroid cancer to eliminate residual malignant tissue after thyroidectomy and to treat metastasis. Because of the low dose of radioiodine used to treat thyroid cancer patients, leukemia is an uncommon complication of exposure to radioiodine. Here, we present a patient who developed therapy-related acute myeloid leukemia with inv(16)(p13.1q22);CB...

The development of Grave’s ophthalmopathy following radioiodine treatment for Grave’s disease is well recognized. However, development of Grave’s ophthalmopathy following radioiodine therapy given for toxic adenoma or toxic nodular goiter has been reported but very rarely. Hereby, we reported a case of a 69-year-old male patient who developed ophthalmopathy after receiving 30 mCi (1110 mBq) 131...

PURPOSE This retrospective study was aimed at revealing the safety and short-term outcome of radioiodine treatment in patients with Graves' disease at outpatient clinic. METHODS From July 1999 to April 2002, 511 patients with Graves' disease were treated with radioiodine at the outpatient clinic of Tajiri Thyroid Clinic, Kumamoto. Of them, 73 patients dropped out or were referred to another m...

introduction:differentiated thyroid carcinoma (dtc) follow-up after thyroidectomy and radioiodine-ablation is performed mainly by thyroglobulin (tg), diagnostic iodine-131 whole body scan (dxwbs) and sonography. some patients with undetectable tg have thyroid-bed uptake after ablation in whom decision making regarding the need for retreatment is still controversial. methods: in this study, we e...

UNLABELLED The long-term dental safety profile of high-dose radioiodine therapy remained elusive despite more than 6 decades of clinical use. METHODS In a cohort study, we investigated the incidence of sialadenitis, xerostomia, caries, and tooth extractions after high-dose radioiodine therapy for differentiated thyroid cancer and explored risk factors by multiple regression models. RESULTS ...